LeonaBio Inc. is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. Its lead drug candidates include lasofoxifene and ATH-1105. LeonaBio Inc., formerly known as Athira Pharma Inc., is headquartered in the Seattle, Washington.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-105.61M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.76 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -340.97% |
| Return on Assets (Trailing 12 Months) | -209.91% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.88 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.88 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $2.98 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | $-24.70 |
| Diluted Earnings per Share (Trailing 12 Months) | $-9.68 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 9.39M |
| Free Float | 7.04M |
| Market Capitalization | $77.31M |
| Average Volume (Last 20 Days) | 0.06M |
| Beta (Past 60 Months) | 2.22 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 25.07% |
| Percentage Held By Institutions (Latest 13F Reports) | 57.12% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |